Anaplastic thyroid cancer: review of precision therapy options and advances
Targeted therapy combinations achieve remarkable responses in anaplastic thyroid cancer when tumors carry specific mutations, transforming what was once uniformly fatal.
This NPJ Precision Oncology review summarizes available precision therapy options for anaplastic thyroid cancer, the most lethal endocrine malignancy, including BRAF/MEK inhibitors for BRAF V600E-positive patients and immune checkpoint inhibitors in biomarker-selected populations. An illustrative case of a ventilator-dependent patient recovering with nivolumab plus vemurafenib demonstrates the potential for remarkable responses in genomically selected ATC.
What the study was
- Study design
- narrative_review_with_case_illustration
- Category
- precision_oncology
- Maturity
- Exploratory
- Journal
- NPJ Precis Oncol
Why it surfaced
Review content only; no original data; ATC has significant unmet need but existing precision therapy paradigm (BRAF/MEK + immunotherapy) is already well-established; SKIP for pipeline given review format.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.